Animal & Veterinary
Visitors from Canada’s Veterinary Drugs Directorate
FDA Veterinarian Newsletter January/February 2006 Volume XVII, No VI
In early January, Dr. Siddika Mithani (center), -Director-General, and Ms. Kathy Dobbin (right), Director Strategic Planning and Stakeholder Relations, of Health Canada’s Veterinary Drugs Directorate (VDD), came to the Center for Veterinary Medicine (CVM) to meet with Center Director Dr. Stephen F. Sundlof (left), and several other members of CVM’s management team, to discuss a variety of issues of joint interest, including ways in which the two agencies could enhance their current cooperative -activities.
Canada’s VDD, like CVM, evaluates and monitors the safety, quality, and effectiveness of animal drugs to protect public and animal health and safety.
Among the topics addressed during the day-long series of meetings were the potential of sharing current Good Manufacturing Practices inspection reports and information on pharmacovigilance activities. The VDD and CVM officials also discussed certain bilateral issues, such as the use in swine of carbadox (which is approved for use in the United States, but not in Canada), aquaculture, and policies on “personal importation” of limited amounts of unapproved drugs from other countries for use in a specific animal.